PTGS2 and gastrointestinal disease: This indicates that PHO patients, especially those with a high prevalence of gastrointestinal diseases should undergo regular blood or endoscopic monitoring during COX-2 inhibitor treatment to prevent more severe adverse effects, such as intestinal ulcers or bleeding.